HA003 - Hatton
Área: 3 - Controle de infecção / Microbiologia / Imunologia

Apresentação: 10/09 (Sexta-feira) - Horário: 08h30 - 10h00 - Sala: 7

Effects of nano-sized sodium hexametaphosphate and fluoride on dual-species biofilms of Streptococcus mutans and Candida albicans
Sampaio C, Delbem ACB, Fernandes AVP, Hosida TY, Morais LA, Camargo ER, Monteiro DR, Pessan JP
Odontologia Infantil e Social - UNIVERSIDADE ESTADUAL PAULISTA - ARAÇATUBA
Conflito de interesse: Não há conflito de interesse

This study evaluated the effects of nano-sized sodium hexametaphosphate (HMPnano), combined or not with fluoride (F), on dual-species biofilms of Streptococcus mutans and Candida albicans. Solutions containing micrometric HMP (HMPmicro) or HMPnano were prepared at 0.5 or 1%, combined or not with 1,100 ppm F; 1,100 ppm F and artificial saliva were tested as positive and negative controls, respectively. Dual-species biofilms of S. mutans and C. albicans, grown in microtiter plates, were treated (1 min) with the solutions at 72, 78 and 96 h from the beginning of their formation. Biofilms were analyzed by colony-forming unit counting (CFU), metabolic activity (XTT assay), and production of total biomass (crystal violet assay). Data were submitted to ANOVA or Kruskal Wallis test, followed by Tukey's or Student-Newman-Keuls' tests (p<0.05). HMPnano at 1% + F led to the highest CFU reduction of S. mutans, followed by HMP micro at 1% + F and positive control (similar to each other), and the remaining groups; CFU counts of C. albicans were not affected by any solution assessed. Furthermore, HMPnano at 1% led to significant lower metabolic activity compared to all other groups (except for HMPnano at 1% + F). Also, all test solutions promoted significant reductions in biofilm biomass compared to both positive and negative controls.
It can be concluded that HMPnano promoted higher antibiofilm effects compared with its micrometric counterpart for most of the variables assessed, besides having a synergist action with F on CFU reduction of S. mutans.
(Apoio: CAPES  N° 001  |  CAPES  N° 88881.068437/2014-01  |  CNPq  N° 123611/2019-9)

---

HA005 - Hatton
Área: 3 - Fisiologia / Bioquimica / Farmacologia

Apresentação: 10/09 (Sexta-feira) - Horário: 08h30 - 10h00 - Sala: 7

Metabolomic identification of novel salivary biomarkers for diagnostic and monitoring Diabetes
Moura DV, Caixeta DC, Santos P, Martins MM, Goulart LR, Sabino-Silva R
Fisiologia - UNIVERSIDADE FEDERAL DE UBERLÂNDIA
Conflito de interesse: Não há conflito de interesse

The diagnostic and monitoring of glycemia is an invasive and painful in diabetes mellitus (DM).Consequently, the search for non-invasive diagnostic biomarkers is of great interest in DM. The limitation to use saliva in clinical settings can be related to the reduced chemical composition knowledge. Here, a characterization of the salivary metabolome is presented in a diabetic animal model. Fluid chromatography coupled to mass spectrometry with time-of-flight system were employed to spot the metabolites in rats saliva. Fifteen Wistar rats were divided in non-diabetic (ND), diabetic (D) and diabetic 6U-treated of insulin (D6U). DM was induced by an intraperitoneal injection (60 mg/kg) of streptozotocin (STZ). The animals were submitted to 28 days of diabetes, and on the 21st day, the insulin- or placebo-treatment was started (#CEUA 13/16). The glycemia and urinary glucose confirmed the diabetic state. The metabolic salivary profile identified hundreds of novel compounds with potential to discriminate diabetes. Principal Component Analysis and clustering indicates 3 main candidates as novel salivary metabolites for salivary screening of diabetes: N-Arachidonoyl tyrosine, 1-11-Eicosenoyl-Triacylglycerol and Dimethylphosphatidylethanolamine (22:5(7Z/24:1(15Z) HMDB, (ANOVA).
Altogether, this salivary metabolomic analysis indicates novel salivary metabolites candidates to be applied in salivary diagnostic salivary platforms for non-invasive diabetic diagnostic platforms and for the salivary monitoring tool during insulin treatment.
(Apoio: CAPES  N° (#23038.014934/2020-59).  |  FAPEMIG  N° (#APQ-02872-16)  |  INCT-TeraNano  N° (465669/2014-0))

---